TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04723797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity program consisting of running and/or cycling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity program consisting of running and/or cycling
Study: NCT06276504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection
Description: Pembrolizumab administration at D0, M1 and M2
Study: NCT04953728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acustimulation (TEA)
Description: Each participant will undergo 5 sessions total at two different frequencies (25 Hz and 100Hz) with electrodes placed at two different locations (wrist and knee) and a placebo session.
Study: NCT05216809

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Physical Activity
Description: Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain \>7,000 steps/day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Physical Activity
Description: Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain \>7,000 steps/day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step-Reduction
Description: Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step-Reduction
Description: Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.
Study: NCT05644522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)
Description: The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)
Description: The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
Study: NCT06519721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Combined with VIC-1911
Description: Oral administration:~Lenvatinib:~Take the clinically normal dose: ≤60Kg body weight, 8mg/day; \>60Kg body weight, 12mg/day;~VIC-1911:~Phase 1: Accelerated titration phase Plan to enroll 3 patients. First, enroll 1 patient, give the initial dose of VIC-1911 25mg BID, observe for 1 week, if there is no dose-limiting toxicity (DLT), increase to 50mg BID. At the same time, enroll another 2 patients, give VIC-1911 25mg BID, observe for 1 week, if no DLT, increase to 50mg BID. Observe for 2 weeks at a dose of 50mg, if no DLT occurs, continue to increase to 75mg BID, observe for 4 weeks. If no DLT occurs, continue to increase by 25mg doses, with an observation period of 4 weeks, until one case of dose-limiting toxicity or two cases of moderate toxicity occur during the titration process, then reduce to the previous dose, and determine it as the final dosing regimen.~Phase 2: Expansion phase According to the final dosing regimen selected, enroll 12 patients and observe for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Combined with VIC-1911
Description: Oral administration:~Lenvatinib:~Take the clinically normal dose: ≤60Kg body weight, 8mg/day; \>60Kg body weight, 12mg/day;~VIC-1911:~Phase 1: Accelerated titration phase Plan to enroll 3 patients. First, enroll 1 patient, give the initial dose of VIC-1911 25mg BID, observe for 1 week, if there is no dose-limiting toxicity (DLT), increase to 50mg BID. At the same time, enroll another 2 patients, give VIC-1911 25mg BID, observe for 1 week, if no DLT, increase to 50mg BID. Observe for 2 weeks at a dose of 50mg, if no DLT occurs, continue to increase to 75mg BID, observe for 4 weeks. If no DLT occurs, continue to increase by 25mg doses, with an observation period of 4 weeks, until one case of dose-limiting toxicity or two cases of moderate toxicity occur during the titration process, then reduce to the previous dose, and determine it as the final dosing regimen.~Phase 2: Expansion phase According to the final dosing regimen selected, enroll 12 patients and observe for 3 months.
Study: NCT04490096

Intervention type: DRUG
Group type: OTHER
Intervention: [11C]-PBR28
Description: A dose of ≤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of \[11C\]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.~Subjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the \[11C\]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner.
Study: NCT03734380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laboratory-based gait retraining (LGR)
Description: Subjects in the LGR group will be encouraged to modify the gait pattern (e.g. adjusting foot progression angle, performing medial knee thrust, and/or lateral trunk lean) to lower their KAM to 80% of respective average baseline KAM obtained during normal unmodified gait. Real-time auditory feedback will be delivered using stereo speakers from both sides of the staircase. A middle C (261.6 Hz) tone and a high-pitched C (4186.0 Hz) of equal intensity will be generated at a footfall below and above the targeted 80% value, respectively. They will be advised to maintain their new gait pattern during their daily living after training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensor-based gait retraining (SGR)
Description: Subjects in the SGR group will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. In addition, the auditory feedback will be delivered through a pair of earphones connected to a smartphone, which has been pre-installed with an app for KAM measurement. They will be advised to maintain their new gait pattern during their daily living after training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise control (Ctrl)
Description: Subjects in the Ctrl group will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups. They will not be given any instructions for out-of-lab activities.
Study: NCT05760469

Intervention type: OTHER
Group type: OTHER
Intervention: Screening
Description: Clinical nurse (CN) notifies research coordinator (RC) about patients with rashes. RC assesses eligibility criteria of patient based on inclusion criteria. RC provide CN with appropriate documentation tool (DT), smart device (SD), standardized red adhesive label (SRAL), and adhesive QRcode. Intervention: With written informed consent, demographic information will be collected. QRcode adhesive will be placed in the DT to track subject documentation throughout the study. Baseline live photograph (LP) of the rash will be taken with SD at day 0. LP will be taken daily. A SRAL, and a QR adhesive code will be included in the LP. LP will be automatically saved in a secure file on the cloud server under the QR code. CN will complete the DT for all rashes included in the study. Treatment of the rash will be at the discretion of the clinical team; the treatment regimen will be recorded daily. The procedure will be repeated daily for all rashes during the patient stay to a maximum of 7 days.
Study: NCT06318013

Intervention type: DIAGNOSTIC_TEST
Intervention: vitality test
Description: A vitality test will be performed using a vitalometer to check if the drowsiness is gone

Intervention type: DIAGNOSTIC_TEST
Intervention: vitality test
Description: A vitality test will be performed using a vitalometer to check if the drowsiness is gone

Intervention type: DIAGNOSTIC_TEST
Intervention: vitality test
Description: A vitality test will be performed using a vitalometer to check if the drowsiness is gone
Study: NCT05241093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYML-122; cytarabine
Description: HYML-122 is administered orally consecutive with 400mg bid or 600mg bid or dose adjusted by DMC judgement in each 28-day treatment cycle. cytarabine is administered by intravenous infusion with 100mg/m2 or dose adjusted by DMC judgement once daily on the first to 7th day of each treatment cycle. Upon completion of each 28-day treatment cycle, patients may continue to receive HYML-122 and cytarabine if they are benefit from the treatment and the toxicity is tolerable.
Study: NCT06342505

Intervention type: PROCEDURE
Intervention: Venipunctures
Description: Extra venipunctures
Study: NCT04354636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver modified atraumatic restorative treatment
Description: Silver diamine fluoride that will be applied during atraumatic restorative treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic restorative treatment
Description: Using atraumatic restorative treatment without applying silver diamine fluoride
Study: NCT05862103

Intervention type: OTHER
Intervention: Treatment Strategies
Description: AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion
Study: NCT06444841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital - Google Calendar
Description: Digital calendar apps allow one to digitally off-load intentions either by typing them or by speaking them (speech-to-text voice-dictation capabilities). In addition, they deliver automated reminders to perform intended tasks, either at a single time (e.g., Monday at 9 am) or at recurring times (e.g., every night at 8 pm).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based - Memory Support System
Description: The Memory Support System is an established paper-based solution for prospective memory functioning. There is considerable evidence in the literature for its utility in mild cognitive impairment (MCI) and it has face validity to patients as supporting memory.
Study: NCT04858048

Intervention type: PROCEDURE
Intervention: Anesthesia
Description: 2 types of anesthesia (general and WALANT) performed during the surgery

Intervention type: PROCEDURE
Intervention: Anesthesia
Description: 2 types of anesthesia (general and WALANT) performed during the surgery
Study: NCT04153396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The Treatment group
Description: The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection(betamethasone propionate 5mg and betamethasone sodium phosphate 2mg per 1ml) added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The Control group
Description: The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
Study: NCT04941287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT06404411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned interventions
Description: Combined aerobic endurance exercise in the control group: individualized exercise prescription, including 5-10 minutes of pre-exercise dynamic stretching and warm-up, 10-30 minutes of formal aerobic exercise, and 5-10 minutes of post-exercise stretching, formal aerobic exercise using a power bike starting from low-intensity and gradually increasing to medium-high-intensity, with a frequency of five times per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation
Description: Adoption of conventional rehabilitation, drug therapy, enhanced nutritional support and other conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: Adoption of conventional rehabilitation, drug therapy, enhanced nutritional support and other conventional treatment
Study: NCT06452160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGC515
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGC515
Description: Capsules for oral administration
Study: NCT05564832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine 1.25% Eye drop
Description: One millimeter of pilocarpine eye drop (Bakhtarbiochemistry Company, Iran) contains pilocarpine hydrochloride 1.25% (12.5 mg) as an active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. The medication preservative is 0.0075% benzalkonium chloride. Inactive ingredients in the ophthalmic are boric acid, sodium citrate dihydrate, sodium chloride, purified water. Another pilocarpine eye drop was Vuity® (1.25% pilocarpine; Allergan company) contains the active intergradients of pilocarpine hydrochloride 1.25% (12.5 mg/mL), equivalent to 1.06% (10.6 mg/mL) pilocarpine free-base and the preservative agents was 0.0075% benzalkonium chloride.
Study: NCT05251103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: time-restricted feeding trial
Description: The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: time-restricted feeding trial
Description: The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.
Study: NCT05389410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO 7
Description: Participant will receive 7 days of NPWT following revision hip or revision knee surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO 7
Description: Participant will receive 7 days of NPWT following revision hip or revision knee surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO 14
Description: Participant will receive 14 days of NPWT following revision hip or revision knee surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO 14
Description: Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
Study: NCT06361498

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound Imaging
Description: Participant will receive ultrasound imaging to evaluate the replaced G-tube placement.
Study: NCT05166265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcutaneous bone conduction hearing system
Description: The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.
Study: NCT04245566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization (PAE)
Description: Prostatic artery embolization will be performed under local anesthesia according to well established and standardized techniques.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacotherapy
Description: Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations
Study: NCT05773183

Intervention type: DRUG
Intervention: Testosterone
Description: In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post

Intervention type: DRUG
Intervention: GnRH
Description: 20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
Study: NCT05861726

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: a moderate kind of physical activity with a heart rate between 65 \& 70% maximum heart rate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: None (control group)
Description: None (the control group)
Study: NCT05561400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 5x5 saline-soaked sponge electrodes will be used with the cathode placed over the right cerebellar hemisphere; 1cm under and 4cm lateral of the inion targeting lobule VII and the anode will be placed on the right shoulder. The electrode placement will be the same across both conditions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sham tDCS to the right cerebellum
Study: NCT04604704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone at 4.5 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAD+
Description: NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.
Study: NCT04941287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlilumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlilumab
Description: Given IV
Study: NCT03550352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg)
Description: Participants will start by taking 1 capsule twice daily for 1 week (5 mg THC/5 mg CBD) and increase the number of capsules as tolerated to a maximum of 6 capsules taken throughout the day by weeks 5-12 (15 mg THC/15 mg CBD total per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TN-C200M2 oral capsules (CBD 200 mg)
Description: Participants will start by taking 1 capsule once daily for 1 week (200 mg CBD) and increase the number of capsules as tolerated to a maximum of 4 capsules taken throughout the day by weeks 5-12 (800 mg CBD total).
Study: NCT06141070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard systemic therapy + radiotherapy
Description: Combined systemic therapy + radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard systemic therapy
Description: Chemoimmunotherapy or immunotherapy
Study: NCT05439824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYS6006 20 μg
Description: SARS-CoV-2 mRNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYS6006 30 μg
Description: SARS-CoV-2 mRNA Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05557786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation
Description: Cerebellar Transcranial Alternating Current Stimulation（tACS）

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation
Description: Cerebellar Transcranial Alternating Current Stimulation（tACS）
Study: NCT05596708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.
Study: NCT05628636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-01-VA
Description: formulation of tricaprilin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-01-VA
Description: formulation of tricaprilin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-01-VA
Description: formulation of tricaprilin